DMAC - DiaMedica Therapeutics Inc
IEX Last Trade
3.915
-0.025 -0.639%
Share volume: 14,240
Last Updated: Fri 30 Aug 2024 09:57:30 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.94
-0.03
-0.64%
Fundamental analysis
22%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
16%
Performance
5 Days
-1.75%
1 Month
8.86%
3 Months
41.88%
6 Months
29.70%
1 Year
33.22%
2 Year
123.93%
Key data
Stock price
$3.92
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.94 - $4.07
52 WEEK CHANGE
$0.28
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO:
Region: US
Website: diamedica.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: diamedica.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
diamedica therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases. for more information please visit www.diamedica.com.
Recent news